Navigation Links
New Race –Specific drug

World's first race-specific medicine has been developed to resolve the controversy over// whether black people are genetically different from whites.

BiDil, a drug combination for treating heart failure, has proved three times more effective in black patients than it has for their white counterparts, its manufacturer claims. If approved by the FDA, it would be the first drug ever to be licensed for use by a single ethnic group.

The results of clinical trials are testament to BiDil's value. In trials, it improved survival rates among black people who had suffered heart failure by 47 per cent. In white patients, the figure was only 15 per cent.

BiDil works by boosting the level of nitrous oxide in the walls of the body's arteries and capillaries, allowing them to expand and thereby reducing the body's blood pressure. In turn, this reduces overall strain on the heart. It proved more effective in African-American patients because they have naturally lower levels of nitrous oxide in their blood and long-term high blood pressure is usually the cause of heart failure.

In contrast, the leading causes of heart failure among white people are clogged arteries and damage to the cardiac muscle caused by previous heart attacks. The issue of whether biological differences can be determined by one's ethnic origins is a long-standing one, and it raises a number of legal and ethical questions. There is a powerful lobby which is in favour of racial profiling when it comes to drug development, backed by evidence that suggests a degree of truth in the ethnicity theory. The reasons for the difference in response to a drug are unclear although it is thought that genes play a major role.

Type-2 diabetes is more common among people from the Indian subcontinent and is thought to be due to a combination of genetic factors and environmental ones. It has also been shown that cases of increased heart weight - an abnormality that can cause heart attacks, heart failure and stroke - is up to three times more prevalent among African-Americans than whites. These exciting results suggest the extent to which even the early stages of heart disease could be prevented in the African-American community by prevention and treatment of hypertension.


'"/>




Related medicine news :

1. Dr Reddy’s Laboratories to challenge patents on drug
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: